It's not uncommon for fragile countries to seize pension assets. That's far less likely in America, but the government still poses a risk to retirement saving
The retailer has pledged to spend an additional $250 billion over the next 10 years on U.S.-made products
Obama can reassure the public and instill confidence that the investigation will be conducted properly
A credit card-size computer lets students choose among 10 operating systems
Oil majors are committing more than $90 billion to oil that costs a lot to extract—deepwater oil deposits, drilling in the Arctic, Canadian oil sands. If prices crash, those companies will be seriously exposed
The deceptively simple symbol is packed with allusions
States whose residents most frequently mention kale on Twitter correlate with liberal voting, while those tweeting about bacon are distinctly more conservative
Banks such as Goldman are giving employees more time off, and young analysts say the changes are making their lives more fun
A law intended to curb demand for material from poachers has antique dealers shopping for real estate
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."